Another report showed that nuclear respiratory factor 2 (NRF2) pathway can be exploited for therapeutic targeting of chronic lymphocytic leukemia (CLL) with ATM null phenotype13. The gene discussed is GABPB1; the disease is B-cell chronic lymphocytic leukemia.